» Articles » PMID: 39585605

High-Fidelity Clinical Simulation to Improve a Pediatric Clinical Trial Design: Lessons Learned and Conceptualization of the Return on Investment (ROI) and Return on Engagement (ROE) Analysis

Overview
Journal Paediatr Drugs
Specialties Pediatrics
Pharmacology
Date 2024 Nov 25
PMID 39585605
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Clinical trials entail complex processes that are more challenging when they are addressed to pediatric patients and include a decentralized design. High-realistic simulation allows for the testing and refining of procedures, organizational systems, and interactions between professionals and patients/families, narrowing the gap between work-as-imagined and work-as-done.

Objectives: The aim of this research was to analyze the impact of simulation in three key moments of a clinical trial: the baseline visit, home administration of the investigational drug by parents, and the drawing and processing of pharmacokinetics samples by a home nurse.

Methods: Multidisciplinary meetings were held between the team of Barcelona Children's Hospital and the sponsor to define the simulation objectives. Three simulation scenarios were executed in 2 days. Subsequently, a post-process analysis was performed, including the assessment of the patient/family experience.

Results: In the baseline visit scenario, minimum duration was calculated, and main aspects related to task dynamics, materials, and training were identified. In the drug administration scenario, the family was able to carry out the infusion within the time established in the protocol, but with some difficulties. In the home nursing scenario, some recommendations for improving safety and patient experience were suggested.

Conclusions: High-realistic clinical simulation can contribute to anticipate risks, refine the design of activities, and to identify specific needs prior to the protocol finalization, a timepoint in the process when modifications can still be made that constitutes a significant return on investment and return on the engagement, in the experience of the patients that will participate in the study.

Clinicaltrial:

Gov Identifier Number: NCT04644575.

References
1.
Dube M, Reid J, Kaba A, Cheng A, Eppich W, Grant V . PEARLS for Systems Integration: A Modified PEARLS Framework for Debriefing Systems-Focused Simulations. Simul Healthc. 2019; 14(5):333-342. DOI: 10.1097/SIH.0000000000000381. View

2.
Ventre K, Barry J, Davis D, Baiamonte V, Wentworth A, Pietras M . Using in situ simulation to evaluate operational readiness of a children's hospital-based obstetrics unit. Simul Healthc. 2014; 9(2):102-11. DOI: 10.1097/SIH.0000000000000005. View

3.
Diaz M, Dawson K . Use of simulation to develop a COVID-19 resuscitation process in a pediatric emergency department. Am J Infect Control. 2020; 48(10):1244-1247. PMC: 7402106. DOI: 10.1016/j.ajic.2020.07.032. View

4.
Cheng K, Mahler F, Lutsar I, Nafria Escalera B, Breitenstein S, Vassal G . Clinical, methodology, and patient/carer expert advice in pediatric drug development by conect4children. Clin Transl Sci. 2022; 16(3):478-488. PMC: 10014692. DOI: 10.1111/cts.13459. View

5.
Michaels D, Lamberti M, Pena Y, Kunz B, Getz K . Assessing Biopharmaceutical Company Experience with Patient-centric Initiatives. Clin Ther. 2019; 41(8):1427-1438. DOI: 10.1016/j.clinthera.2019.07.018. View